Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Cooper

Showing results (171-180 of 399) with videos related to

Pageof 40
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 25, 2006
PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouseAnna C Calkin, Sara Giunti, Karin A Jandeleit-Dahm, et al.
Hypertension (Dallas, Tex. : 1979)|June 1, 2012
Activation of the Renin-Angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouseChris Tikellis, Raelene J Pickering, Despina Tsorotes, et al.
Diabetes|May 10, 2014
Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetesChris Tikellis, Raelene J Pickering, Despina Tsorotes, et al.
Kidney Medicine|February 29, 2024
Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME TrialSamy Hadjadj, Mark E Cooper, Dominik Steubl, et al.
Circulation|March 17, 2004
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosisRiccardo Candido, Terri J Allen, Markus Lassila, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 1, 2019
Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME TrialMark E Cooper, Silvio E Inzucchi, Bernard Zinman, et al.
Diabetes, Obesity & Metabolism|February 11, 2020
Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trialMark E Cooper, Julio Rosenstock, Takashi Kadowaki, et al.
International Urology and Nephrology|January 3, 2021
Clinicopathologic features and prognostic factors in older patients with biopsy-proven diabetic nephropathyLijun Zhao, Honghong Ren, Rui Zhang, et al.
Kidney International|April 23, 2002
Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expressionJohn Kanellis, Kathy Paizis, Alison J Cox, et al.
International Journal of Molecular Sciences|March 13, 2025
Induced Genetic Deletion of Cell Division Autoantigen 1 in Adulthood Attenuates Diabetes-Associated Renal FibrosisPacific Huynh, Yuxin Yang, Hua Tian, et al.
Pageof 40

Showing results (171-180 of 399) with videos related to

Sort By:
Pageof 40
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 25, 2006
PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouseAnna C Calkin, Sara Giunti, Karin A Jandeleit-Dahm, et al.
Hypertension (Dallas, Tex. : 1979)|June 1, 2012
Activation of the Renin-Angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouseChris Tikellis, Raelene J Pickering, Despina Tsorotes, et al.
Diabetes|May 10, 2014
Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetesChris Tikellis, Raelene J Pickering, Despina Tsorotes, et al.
Kidney Medicine|February 29, 2024
Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME TrialSamy Hadjadj, Mark E Cooper, Dominik Steubl, et al.
Circulation|March 17, 2004
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosisRiccardo Candido, Terri J Allen, Markus Lassila, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 1, 2019
Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME TrialMark E Cooper, Silvio E Inzucchi, Bernard Zinman, et al.
Diabetes, Obesity & Metabolism|February 11, 2020
Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trialMark E Cooper, Julio Rosenstock, Takashi Kadowaki, et al.
International Urology and Nephrology|January 3, 2021
Clinicopathologic features and prognostic factors in older patients with biopsy-proven diabetic nephropathyLijun Zhao, Honghong Ren, Rui Zhang, et al.
Kidney International|April 23, 2002
Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expressionJohn Kanellis, Kathy Paizis, Alison J Cox, et al.
International Journal of Molecular Sciences|March 13, 2025
Induced Genetic Deletion of Cell Division Autoantigen 1 in Adulthood Attenuates Diabetes-Associated Renal FibrosisPacific Huynh, Yuxin Yang, Hua Tian, et al.
Pageof 40